The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Primary analysis from the phase 2 study of continuous talazoparib (TALA) plus intermittent low-dose temozolomide (TMZ) in patients with relapsed or refractory extensive-stage small cell lung cancer (ES-SCLC).
 
Jonathan W. Goldman
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly; Pfizer
Research Funding - Abbvie (Inst); Advaxis (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst); Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Amy Lauren Cummings
Consulting or Advisory Role - OncLive/MJH Life Sciences; Tempus
Research Funding - Amgen Foundation; Genentech (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending for bioinformatics approach to identification of motif neoepitopes
 
Melody A. Mendenhall
No Relationships to Disclose
 
Maria A Velez
No Relationships to Disclose
 
Sunil Babu
Employment - Fort Wayne Medical Oncology & Hematology
Stock and Other Ownership Interests - Fort Wayne Medical Oncology & Hematology; Lutheran hospital (I)
Honoraria - Alexion Pharmaceuticals; AstraZeneca; Bayer; Beigene; Bristol-Myers Squibb; Castle Biosciences; Kite, a Gilead company; Lilly; pharmacosmos
Consulting or Advisory Role - Alexion Pharmaceuticals; Amgen; argenx; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen Oncology; Kite, a Gilead company
Speakers' Bureau - Alexion Pharmaceuticals
Research Funding - Abbvie (Inst); Alexion Pharmaceuticals (Inst); Amgen (Inst); argenx (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Novartis (Inst); Sanofi (Inst); Syndax (Inst); TG Therapeutics (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; Bristol-Myers Squibb; Genentech/Roche; Janssen Oncology; Lilly
 
Tirrell T. Johnson
No Relationships to Disclose
 
Juan M. Alcantar
No Relationships to Disclose
 
Shaker R. Dakhil
No Relationships to Disclose
 
David E. Kanamori
No Relationships to Disclose
 
William E. Lawler
No Relationships to Disclose
 
Sidharth Anand
Honoraria - Curio Science
Consulting or Advisory Role - Signatera
Travel, Accommodations, Expenses - Curio Science
 
James Chauv
No Relationships to Disclose
 
Edward B. Garon
Consulting or Advisory Role - ABL Bio; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Gilead Sciences; GlaxoSmithKline; Lilly; Merck; Natera; Novartis; Personalis; Sanofi/Regeneron; Shionogi; Xilio Therapeutics
Research Funding - ABL Bio (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Diagnosistic and therapeutic use of "Motif Neoepitopes" as defined by Cummings et al in Nature Cancer. (Inst)
 
Dennis J. Slamon
Leadership - Biomarin
Stock and Other Ownership Interests - Amgen; Amgen; BioMarin; Merck Sharp & Dohme; Pfizer; Seagen; Vertex
Honoraria - Novartis
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Seagen
Research Funding - Novartis; Pfizer
Travel, Accommodations, Expenses - Biomarin; Novartis; Pfizer